It seemed like an egregious violation of academic standards. A researcher forwarded us a data access agreement from the University of Oxford, in which Schedule 4 read as follows:
Nature, as we and others have noticed, has had what Paul Knoepfler referred to as a “torrent” of retractions in the past two years. That torrent — 13 research papers — has prompted a welcome and soul-searching editorial, as it did in 2010 when the journal had what it called an “unusually large number” of … Continue reading Nature, facing “considerable rise” in retractions, blames lawyers for opaque and delayed notices
Molecular Vision has issued “full retractions” for a trio of articles by a group of eye researchers. All of the articles were led by Azza El-Remessy, director of the University of Georgia College of Pharmacy’s clinical and therapeutic graduate program. As much as that is, there might be more still with this case. The first … Continue reading Molecular Vision retracts three papers from University of Georgia group with error-ridden images
This week at Retraction Watch featured revelations about legal threats to PubPeer, and a swift expression of concern for a paper denying the link between HIV and AIDS. Here’s what was happening elsewhere:
Here at Retraction Watch, the week featured the revelations of the peer reviews of an early version of the STAP stem cell paper, and an announcement about a new partnership. Here’s what was happening elsewhere:
Last month, we brought you the story of the retraction of a paper by Nobutu Yamamoto and colleagues about “a protein being used — unapproved by health agencies — to treat diseases including cancer and autism.” A second paper by the group, about using the protein to treat HIV, has been retracted. Here’s the notice … Continue reading Second study of widely touted cancer and HIV “cure” retracted
Another busy week at Retraction Watch. Here’s what was happening elsewhere:
Another busy week at Retraction Watch. Here’s what was happening elsewhere: “Why are dope-addicted, disgraced doctors running our drug trials?” asks Peter Aldhous. Could a biology student in Colombia be jailed for violating copyright?
A panel reviewing The BMJ‘s handling of two controversial statin papers said the journal didn’t err when it corrected, rather than retracted, the articles. The articles — a research paper and a commentary — suggested that use of statins in people at low risk for cardiovascular disease could be doing far more harm than good. Both … Continue reading Panel says BMJ was right to not retract two disputed statin papers
A group of researchers in China has lost their paper on liver cancer after the first author admitted to duplication, also known, inelegantly, as self-plagiarism. The paper, “Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells,” appeared in the July 2013 issue of the Journal of Drug … Continue reading “Lack of experience and understanding” forces duplication retractions of liver cancer paper